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Abstract We discussed whether we are able to select a
subgroup of patients with osteopenia having a high fracture
risk, in which anti-osteoporotic drug treatment can be
advocated. We concluded that in individuals in whom, based
on clinical risk factors, a dual-energy x-ray absorptiometry
(DXA) was performed in which osteopenia was diagnosed,
anti-osteoporotic treatment should be prescribed in those
patients with prevalent vertebral fractures, and in patients
chronically using glucocorticoids, in a dosage of 7.5 mg per
day or more. Although recent developments with regard to
high-resolution imaging techniques (eg, peripheral quantitative
computed tomography) seem to be promising, until now they
do not provide substantial more reliable information than DXA
in the prediction of fractures. We think that more data are
urgently needed, since safe and effective drugs are available,
but there is uncertainty to which patients with osteopenia these
drugs should be prescribed.
Keywords Osteopenia . Glucocorticoids . Vertebral
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Clinical Trial Acronyms
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MORE Multiple Outcomes of Raloxifene Evaluation
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Introduction
In daily practice, postmenopausal women and elderly men
are usually treated for osteoporosis based on a low bone
mineral density (BMD), namely a T-score of ≤−2.5 at the
lumbar spine and/or hips. However, it is important to realize
that this arbitrarily chosen cutoff point is based on the 1994
World Health Organization defined subcategories of BMD.
The different categories are given in Table 1. These cutoff
values were originally defined to assess the prevalence of
osteoporosis, and not, as is common practice nowadays, to
be used as a treatment threshold [1].
Based on these categories, both osteopenic and osteopo-
rotic patients are treated with dietary and lifestyle management
(adequate calcium and vitamin D intake, exercise therapy, and
prevention of falls), whereas those with T-scores in the
osteoporotic range are also prescribed anti-osteoporotic drugs,
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usually (generic) bisphosphonates. However, it is important to
realize that, paradoxically, more fractures occur in patients
with osteopenia than in patients with osteoporosis. For
instance, in the NORA (National Osteoporosis Risk Assess-
ment) study, a large, population-based observational study in
postmenopausal women in North America, it was found that
the incidence of clinical fractures was higher in patients with
T-scores in the osteoporotic range than in patients with T-scores
in the osteopenic range, but the total number of clinical
fractures was higher in osteopenic patients than in osteoporotic
patients [1].
The same pattern was found in a recent study in
Australia, in which 57% of fractures occurred in patients
with osteopenia, and only 27% in patients with osteoporosis
[2]. The explanation for this phenomenon is simple: the
number of patients with osteopenia is much higher than the
number of patients with osteoporosis.
Strikingly, several effective anti-osteoporotic drugs are
available, but these drugs are usually only prescribed in the
high-risk group of osteoporotic patients, but not in the
much larger group of individuals with osteopenia. In this
manuscript, we will discuss the critical question whether we
are able to categorize within the individuals with osteopenia,
subgroups of high-risk patients, whom anti-osteoporotic drug
treatment should be advocated.
Bone Quality and Osteopenia
In clinical practice, BMD is assessed by dual-energy x-ray
absorptiometry (DXA) as the current gold standard test for
diagnosing osteoporosis. The relationship between BMD
and fracture risk has clearly been established [3]. DXA uses
a two-dimensional representation of a three-dimensional
structure and expresses the amount of bone in grams per
centimeter squared. Recent clinical investigations indicate
that BMD only partly explains bone strength and show
limitations of BMD measurements in assessing fracture risk
and monitoring the response to therapy [1, 4–7].
Bone quality is defined as the properties of bone tissue
that, in addition to density, contribute to bone strength [8].
These properties include the macro- and microarchitecture
and the material properties of bone as well as the efficiency
of microdamage repair. Thus, fracture risk is strongly
related to bone quality.
Newnoninvasive and/or nondestructive imaging techniques
have been developed enabling quantitative assessment of
macro- and microstructural bone features, and improving our
ability to estimate bone strength. At present the quality of bone
can be partly assessed in daily practice. Quantitative assess-
ment of bone macrostructure can be provided by DXA and CT,
particularly volumetric quantitative computed tomography
(QCT), whereas assessment of the trabecular and cortical
microstructure may be obtained by high-resolution CT and
high-resolution MRI.
In recent studies it has been shown that women undergo
loss of trabeculae with an increase in trabecular spacing,
whereas men mainly sustain trabecular thinning with aging
but no net change in trabecular number or spacing [9–11•].
Because decreases in trabecular number have been shown
to have a much greater impact on bone strength compared
with decreases in trabecular thickness, these findings may
help explain the lower risk of fractures in men [12].
Additionally, women have less periosteal expansion, more
porous cortices during aging [10, 12].
Kazakia et al. [13] showed that osteopenic individuals
with identical BMD at the distal radius may have
substantial differences in bone parameters that reflect bone
quality and bone strength. Comparison of postmenopausal
women with and without a fracture showed no difference in
areal BMD of the lumbar spine or hip and only a small
difference at the distal radius between both groups, whereas
there were substantial and highly significant differences in
volumetric BMD, microarchitecture, and bone mechanical
properties assessed by high-resolution peripheral QCT
(HR-pQCT) [14]. Moreover, it has recently been shown
by theMrOS (Osteoporotic Fractures inMen) Research Group
that peripheral bone strength measures assessed by peripheral
QCT are associated with fracture risk and may improve the
ability to identify older men at high risk of fracture [15•].
Thus, based on the recent developments and literature,
assessment of macro- and microstructural bone features by
high-resolution (peripheral CT) techniques can provide
additional information regarding bone quality in finite
element analysis–derived bone strength, independently of
DXA. However, the application of these new imaging
techniques for daily practice, especially with regard to
selection of individual patients with high fracture risk and
treatment decisions, needs to be further studied.
Glucocorticoids and Osteopenia: A Combination
with High Fracture Risk
Glucocorticoids (GCs) are often used because of their
strong anti-inflammatory and immunomodulating effects.






Established osteoporosis T≤−2.5 in the presence of
one or more fragility fractures
168 Curr Osteoporos Rep (2011) 9:167–172
However, their use is limited because of the large number of
side effects. Osteoporosis is regarded as one of the most
serious side effects, because the bone loss is irreversible
and the clinical manifestations, vertebral and nonvertebral
fractures, may be devastating [16]. GCs have a direct
negative effect on bone formation, by increasing apoptosis
of osteoblasts and osteocytes, which is reflected in low
bone formation markers (eg, osteocalcin) [16]. Conversely,
bone resorption may be elevated in the initial phase, related
to high levels of receptor activator of nuclear factor-κB
ligand; the combination of low bone formation and elevated
bone resorption may lead to rapid bone loss and fractures.
Later on, bone resorption is depressed in chronic GC users,
probably resulting from the coupling between bone formation
and bone resorption [17, 18••].
In addition, GCs negatively influence calcium homeo-
stasis by decreasing calcium absorption in the gut and
calcium reabsorption in the kidney, and have unfavorable
neuroendocrine and neuromuscular effects. In a very large
observational study, it has been shown that the risk for
clinical fractures is dose related: for example, for hip
fractures, there is no elevated risk in prednisone users with
a mean daily dosage of less than 2.5 mg per day, whereas in
those with dosages between 2.5 to 7.5 mg/day the relative
risk (RR) was 1.77 (95% CI, 1.6–2.0) and in those between
7.5 mg per day the RR was 2.27 (95% CI, 1.9–2.7). The
same pattern was found for vertebral fractures: an RR of 1.6
in patients using less than 2.5 mg of prednisone per day up
to an RR of 5.2 in those using more than 7.5 mg per day
[16]. These data show that fracture risk is dose related, but
it is important to realize that higher dosages are prescribed
to patients with higher disease activity, and that the
underlying disease activity also has strong effects on bone
(metabolism). Therefore, it might be more appropriate to
use the term GC-associated osteoporosis, instead of GC-
induced osteoporosis. There is an ongoing discussion about
whether the fracture threshold for BMD is changed during
the use of GC: Van Staa et al. [19] showed that the risk for
vertebral fractures was two to three times higher in GC
users versus non-GC users (for the same BMD).
For all these reasons, it can be argued to use a lower
threshold for initiating anti-osteoporotic drugs in GC
users than in postmenopausal women and elderly men.
For chronic users, it has been advocated in the past to
have a cutoff value of T-score less than −1 SD
(according to American College of Rheumatology
Glucocorticoid-Induced Osteoporosis Guidelines 2001)
or T-score less than −1.5 in the UK Consensus document
[20, 21]. Because fracture risk is higher in starters, and
particularly in the elderly, it can be advocated to start
treatment of all osteopenic patients 50 years and over with
prednisone in a dosage of 7.5 mg per day or more for at
least 3 months.
Vertebral Fractures and Osteopenia
Vertebral fractures are often missed. For instance, Gehlbach
[22] showed that only 50% of vertebral fractures were
recognized by radiologists, and anti-osteoporotic treatment
was started in only 25% of these patients. It is generally
thought that vertebral fractures are often not diagnosed
because they are usually not related to trauma and fall
events, and thus more difficult to recognize than non-
vertebral fractures. Also, they can be missed in the
search for other diseases (malignancy), or by under-
estimating the clinical relevance of diagnosing a vertebral
fracture [23]. However, prevalent vertebral fractures are
associated with a four times higher risk for new vertebral
fractures, and a two times higher risk for hip fractures
[24]. Lindsay et al. [25] showed that in 20% of the women
with an incident vertebral fracture a subsequent vertebral
fracture occurred. In addition, the presence of prevalent
vertebral fractures is associated with a decreased quality of
life [26]. For these reasons, diagnosing vertebral fractures
is clinically relevant. Interestingly, it is nowadays possible
to detect vertebral deformities with lateral vertebral
assessment (LVA), a software technique imaging the
heights of the vertebral bodies that can be used in one
session with a BMD measurement of the spine and hips.
LVA has the additional advantage of a lower radiation
dosage.
How to score vertebral fractures? In most clinical trials,
the semiquantitative method of Genant is used, in which a
height loss of at least 20% is arbitrarily defined as a
vertebral fracture [27]. Because in comparative studies with
conventional radiographs (regarded as the gold standard)
the sensitivity and specificity of diagnosing vertebral
fractures was slightly lower with LVA, particularly in the
upper thoracic region, we propose to use a height loss of at
least 25% for defining a vertebral fracture by LVA. The
finding of a height loss of 25% or more can be used as a
threshold for making decisions for starting anti-osteoporotic
treatment, usually for 5 years.
The added value of diagnosing a vertebral fracture in
a patient with a T-score in the osteoporotic range is
limited, since the decision for anti-osteoporotic treat-
ment can be based on the presence of clinical risk
factors and the low T-score. In contrast, the consequence
of the presence or absence of a vertebral deformity in
patients with osteopenia might differ from starting
treatment or not. In several studies it has been shown
that in around 20% of the patients with osteopenia a
vertebral fracture can be diagnosed [28, 29•]. In line with
this, we propose that it is necessary that LVA software
becomes widely available, and that radiologists and
physicians are adequately trained in detecting vertebral
fractures.
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Osteopenia: Evidence for Treatment of Certain
Patients?
Up to now there is no consensus on how patients with low
BMD should be treated, as the terms osteopenia and
osteoporosis were introduced for diagnostic purposes (to
classify patients according to BMD) and not for therapeutic
thresholds, thus without direct therapeutic consequences.
Therefore, osteopenic patients should not be treated without
any other indication for anti-osteoporotic medication.
Literature regarding medical treatment of patients with
osteopenia is sparse, as most clinical trials focus on patients
with osteoporosis and/or the presence of hip or vertebral
fractures as inclusion criteria. However, some randomized
controlled trials also included osteopenic patients, and data
of these studies allowed post hoc analyses in these patients.
Three Different Types of Studies Can Be Discriminated
Studies with Osteopenic Patients
In a post hoc analysis of the FIT-1 and FIT-2 studies in
patients with osteopenia of the femoral neck (with a T-score
between −1.6 and −2.5 SD, with and without prevalent
vertebral fractures), alendronate decreased the risk of
radiologic vertebral fractures (RR, 0.57; 95% CI, 0.41–
0.81) and clinical vertebral fractures (RR, 0.41; 95% CI,
0.19–0.76) [30]. In a post hoc analysis of the SOTI and
TROPOS studies in patients with vertebral osteopenia (with
a prevalent vertebral fracture or a previous nonvertebral
fracture) and in patients with osteopenia at the spine and
hips (in which vertebral fracture occurred in 48% to 52%
and previous nonvertebral fracture in 22% to 29%),
strontium ranelate decreased the risk for vertebral fractures
in patients with vertebral osteopenia (RR, 0.59; 95% CI,
0.43–0.82) and in patients with osteopenia at both sites
(RR, 0.48; 95% CI, 0.24–0.96) [31]. However, most of
these patients also had other risk factors (eg, previous
vertebral or nonvertebral fractures, chronic stay in rest
home, repeat falls, or family history of fractures). In a post
hoc analysis from the MORE study in patients with
osteopenia of the total hip, raloxifene (60 mg/day)
decreased the risk on radiologic and clinical fractures [32].
Studies in Patients with Prevalent Fractures,
Without BMD Inclusion Criterion
In a primary analysis, risedronate diminished the risk of
radiologic vertebral deformities in patients with a vertebral
fracture at baseline. The mean T-score in the spine at
baseline was −2.6 SD (1.4), also indicating that patients
without osteoporosis were included [33]. Hip fracture
patients were included in only one study with fractures as
a primary end point. In this study, the use of zoledronate
was associated with a lowered RR for vertebral and
nonvertebral fractures. At baseline, 59% of the patients
had a T-score at the femoral neck above −2.5 [34].
Studies with Inclusion of Both Osteoporotic
and Osteopenic Patients
In several phase 3 studies patients were included with a
mean T-score above −2.5 SD: in the North American
risedronate study mean BMD was −2.4 SD [35]; in an
ibandronate study −1.8 SD (in the total hip) [36]; in a study
with parathyroid hormone (1–84) -1.9 and −2.2 SD (in the
total hip and femoral neck, respectively) [37]; with
strontium ranelate −2.4 [38]; and with denosumab −2.2
and −1.9 SD, at the femoral neck and total hip, respectively
[39]. In the teriparatide study both patients with a mild
vertebral fracture and patients with two mild vertebral
fractures and a T-score of less than −1.0 SD at the hip or
lumbar spine were included [40]. All above-mentioned
studies included patients with a prevalent vertebral fracture
with the exception of the denosumab trial, in which only
24% of patients had prevalent vertebral fracture.
Taken together, these data emphasize that anti-
osteoporotic drug treatment is effective, particularly in
those patients with prevalent vertebral fractures or previous
(recent) nonvertebral fractures.
Conclusions
The critical point is that the majority of fractures occur in
patients with osteopenia, whereas the effective and gener-
ally safe anti-osteoporotic drugs are usually only prescribed
in osteoporotic patients. Although lifestyle measures are
advocated in osteopenic patients, among which include
adequate calcium and vitamin D supplementation, the
question arises which subgroups of osteopenic patients
can be defined in whom anti-osteoporotic drugs should also
be prescribed. Prescription of these drugs to all osteopenic
patients will certainly lead to overtreatment with unneces-
sary side effects and costs. Theoretically, it would be very
attractive to get additional information on bone strength and
fracture risk above DXA results with high-tech measure-
ment techniques such as HR-pQCT; unfortunately, these
data hardly exist, and these machines are (still) very
expensive, and thus their availability is limited. We hope
that in the coming years more data will support the use of
HR-pQCT in daily practice for estimating the bone strength
in patients in which the fracture risk should be estimated,
and that these machines become less expensive and more
widely available.
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So far, in patients using GCs 3 months or more in a
dosage of ≥7.5 mg/day, particularly in elderly patients and/
or in those with prevalent vertebral fractures, we advocate
prescribing anti-osteoporotic drugs, particularly those drugs
in which reduction of vertebral fractures versus placebo was
documented (in GC users), or the equivalence or even
superiority versus active comparators. The other subgroup we
defined is the group of patients with clinical risk factors for
osteoporosis and/or a recent fracture, in which a DXAwas
performed, with a T-score in the osteopenic range, while a
vertebral deformity was found on radiographs or LVA.
It will be a challenge to diagnose and adequately treat all
osteopenic patients with vertebral deformities and/or the
use of GCs, but the first step is to protect the osteopenic
patients with the highest risk for future fractures. Whether
subjects with a recent clinical fracture and other risk factors
for fractures and osteopenia (eg, documented low bone
quality) will benefit from anti-osteoporosis medication
cannot be concluded from current data but may become
more clear in future studies. These recommendations are
not the end but the beginning: more research is urgently
needed to find out which osteopenic patients benefit form
anti-osteoporotic drug therapy.
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